DDInter904 DDInter875
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Idarubicin {u} (Compound) treats {v} (Disease) breast cancer
Idarubicin {u} (Compound) binds {v} (Gene) CYP2C9
Idarubicin {u} (Compound) upregulates {v} (Gene) MEGF8
Idarubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Idarubicin {u} (Compound) downregulates {v} (Gene) CBR3
Idarubicin {u} (Compound) causes {v} (Side Effect) Haemorrhage
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Idarubicin (Compound) resembles Valrubicin (Compound)
Idarubicin (Compound) treats breast cancer (Disease)
Idarubicin (Compound) binds CYP2C9 (Gene)
Idarubicin (Compound) upregulates MEGF8 (Gene)
Idarubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Idarubicin (Compound) downregulates CBR3 (Gene)
Idarubicin (Compound) causes Haemorrhage (Side Effect)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole